WO2008042941A3 - Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease - Google Patents

Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease Download PDF

Info

Publication number
WO2008042941A3
WO2008042941A3 PCT/US2007/080270 US2007080270W WO2008042941A3 WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3 US 2007080270 W US2007080270 W US 2007080270W WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasculogenesis
treatment
oncology
related disease
humanized anti
Prior art date
Application number
PCT/US2007/080270
Other languages
French (fr)
Other versions
WO2008042941A2 (en
Inventor
Melissa Damschroder
Acqua William Dall
Herren Wu
Emma T Bowden
Original Assignee
Medimmune Llc
Melissa Damschroder
Acqua William Dall
Herren Wu
Emma T Bowden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Melissa Damschroder, Acqua William Dall, Herren Wu, Emma T Bowden filed Critical Medimmune Llc
Publication of WO2008042941A2 publication Critical patent/WO2008042941A2/en
Publication of WO2008042941A3 publication Critical patent/WO2008042941A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

The present invention provides humanized versions of anti-EphB4 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human EphB4 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of human malignancies and vasculogenesis-related disorders and diseases.
PCT/US2007/080270 2006-10-04 2007-10-03 Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease WO2008042941A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82819006P 2006-10-04 2006-10-04
US60/828,190 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008042941A2 WO2008042941A2 (en) 2008-04-10
WO2008042941A3 true WO2008042941A3 (en) 2008-12-11

Family

ID=39269178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080270 WO2008042941A2 (en) 2006-10-04 2007-10-03 Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease

Country Status (1)

Country Link
WO (1) WO2008042941A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008226824A1 (en) * 2007-03-12 2008-09-18 Board Of Regents Of The University Of Texas System Use of EphB4 as a diagnostic marker and a therapeutic target for ovarian cancer
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
JP2013526852A (en) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Circulating biomarkers for disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719971B1 (en) * 1991-06-14 2004-04-13 Genentech, Inc. Method for making humanized antibodies
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719971B1 (en) * 1991-06-14 2004-04-13 Genentech, Inc. Method for making humanized antibodies
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
WO2008042941A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
NL301196I2 (en) inebilizumab
WO2006089133A3 (en) Anti-cd19 antibodies and uses in oncology
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
MY149630A (en) Antibodies against amyloid-beta peptide
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
IL212633A (en) Monoclonal antibody or antigen-binding fragment thereof, pharmaceutical compositions comprising the same and use thereof for the manufacture of medicaments for the treatment of cancer
MX355181B (en) Human antibodies against human tissue factor.
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
MX2009013656A (en) Anti-cd20 therapeutic compositions and methods.
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
UA89350C2 (en) Humanized antibody that specifically binds human cd20
MX2020012567A (en) Anti-ox40 antibodies and methods of use.
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2008152537A3 (en) Humanized monoclonal antibodies
CY1116887T1 (en) ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY
TW202413426A (en) Anti-ccr8 antibodies and methods of use
UA108207C2 (en) HIGH-AFIN HUMAN ANTIBODY TO HUMAN ANGIOPOETIN-2
UA102085C2 (en) ISOLATED MONOCLONAL ANTIBODY THAT BINDS TO hGM-CSF AND COMPOSITION COMPRISING SAME

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07868359

Country of ref document: EP

Kind code of ref document: A2